Page last updated: 2024-12-11

dmp 728

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DMP 728: structure in first source; RN given refers to the monomethane sulfate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9831047
MeSH IDM0226408

Synonyms (17)

Synonym
l-aspartic acid, n-(3-(aminomethyl)benzoyl)-d-2-aminobutanoyl-n-2-methyl-l-arginylglycyl-, cyclic (41-1)-peptide, monomethanesulfonate
n-(3-(aminomethyl)benzoyl)-d-2-aminobutanoyl-n-2-methyl-l-arginylglycyl-l-aspartic acid cyclic (41-1)-peptide, monomethanesulfonate
dmp 728
dmp728
dmp-728
cyclic(d-2-aminobutyryl-n(2)-methyl-l-arginylglycyl-l-aspartyl-3-(aminomethyl)benzoic acid)
cyclic(d-2-aminobutyryl-n-2-methyl-l-arginyl-glycyl-l-aspartyl-3-aminomethylbenzoic acid)methanesulfonic acid salt
xl 118
unii-0bn8ueo84e
155158-97-7
0bn8ueo84e ,
cyclo(n2-methyl-l-arginylglycyl-l-.alpha.-aspartyl-3-(aminomethyl)benzoyl-(2r)-2-aminobutanoyl), monomethanesulfonate
dmp 728 monomethanesulfonate
2-[(5s,11s,14r)-11-[3-(diaminomethylideneamino)propyl]-14-ethyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentazabicyclo[15.3.1]henicosa-1(21),17,19-trien-5-yl]acetic acid;methanesulfonic acid
Q27236576
2-((5s,11s,14r)-14-ethyl-11-(3-guanidinopropyl)-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-1(1,3)-benzenacyclohexadecaphane-5-yl)acetic acid compound with methanesulfonic acid (1:1)
AKOS040745752

Research Excerpts

Effects

ExcerptReferenceRelevance
"DMP 728 has been characterized as a potent and specific platelet glycoprotein IIb/IIIa complex (GPIIb/IIIa) antagonist."( Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist.
DeGrado, WF; Kapil, RP; Lucchesi, BR; Mousa, SA; Mu, DX; Reilly, TM, 1996
)
1.27

Toxicity

ExcerptReferenceRelevance
" Furthermore, DMP 728 did not elicit any other platelet unrelated adverse effects over wide range of doses."( Intravenous antiplatelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP 728 in anesthetized dogs.
Bozarth, J; De Grado, W; Flint, S; Hassell, S; Lorelli, W; Mousa, SA; Reilly, TM, 1994
)
0.87

Bioavailability

DMP 728 demonstrated dose-dependent oral antiplatelet effects with an absolute oral bioavailability of 8% to 12% in dogs.

ExcerptReferenceRelevance
" DMP 728 demonstrated dose-dependent oral antiplatelet effects with an absolute oral bioavailability of 8% to 12% in dogs."( Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist.
DeGrado, WF; Kapil, RP; Lucchesi, BR; Mousa, SA; Mu, DX; Reilly, TM, 1996
)
1.46
"The intestinal absorption of DMP 728, a cyclic peptide fibrinogen antagonist, was examined with the goals of identifying the cause(s) of its low oral bioavailability and understanding the mechanisms of its intestinal transport."( Intestinal absorption barriers and transport mechanisms, including secretory transport, for a cyclic peptide, fibrinogen antagonist.
Aungst, BJ; Saitoh, H, 1996
)
0.59
"The effects of structural modifications on the membrane permeability of angiotensin II (Ang II) receptor antagonists and the usefulness of in vitro and in situ intestinal absorption models in predicting in vivo absorption or bioavailability were investigated."( Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption.
Aungst, BJ; Eyermann, CJ; Huang, SM; Ribadeneira, MD, 1996
)
0.29
"Permeation coefficients (Pa) across Caco-2 cell monolayers correlated well with both in situ absorption rate constants (ka) and in vivo bioavailability or % absorption."( Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption.
Aungst, BJ; Eyermann, CJ; Huang, SM; Ribadeneira, MD, 1996
)
0.29
" Charge, solvation energy, and hydrogen bonding are predominant determinants of intestinal permeability and oral bioavailability of these compounds."( Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption.
Aungst, BJ; Eyermann, CJ; Huang, SM; Ribadeneira, MD, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's24 (92.31)18.2507
2000's2 (7.69)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.81 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.85%)5.53%
Reviews1 (3.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]